Tgf-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes

Journal of Immunology

Volumn 194, Issue 2, 2015, Pages 709-718

  Nurgazieva, Dinara ^a,b   Mickley, Amanda ^a   Moganti, Kondaiah ^a   Ming, Wen ^a   Ovsyi, Illya ^a   Popova, Anna ^a   Sachindra, S ^a   Awad, Kareem ^a   Wang, Nan ^a   Bieback, Karen ^a   Goerdt, Sergij ^a   Kzhyshkowska, Julia ^a,c,d   Gratchev, Alexei ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d TOMSK STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; HEPCIDIN; INHIBITOR OF DIFFERENTIATION 3; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE RECEPTOR; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; HAMP PROTEIN, HUMAN; ID3 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; PLAUR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SMAD1 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMAD5 PROTEIN, HUMAN; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR PROTEIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MATURATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETICS; GENE EXPRESSION REGULATION; HAMP GENE; HUMAN; HUMAN CELL; ID3 GENE; MACROPHAGE ACTIVATION; PLAUR GENE; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; CELL CULTURE; IMMUNOLOGY; MACROPHAGE; PATHOLOGY;

ACTIVIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; HEPCIDINS; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MACROPHAGES; NEOPLASM PROTEINS; PLAQUE, ATHEROSCLEROTIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84920495594     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300272     Document Type: Article

References (55)

1. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
2. Chen, D., P. P. Lemons, T. Schraw, and S. W. Whiteheart. 2000. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 and 4 in lysosome release. Blood 96: 1782-1788.
3. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. the road ahead. Cell 104: 503-516.
4. Griffin, E., A. Re, N. Hamel, C. Fu, H. Bush, T. McCaffrey, and A. S. Asch. 2001. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat. Med. 7: 840-846.
5. Stout, R. D., S. K. Watkins, and J. Suttles. 2009. Functional plasticity of macrophages: In situ reprogramming of tumor-associated macrophages. J. Leukoc. Biol. 86: 1105-1109.
6. Watkins, S. K., B. Li, K. S. Richardson, K. Head, N. K. Egilmez, Q. Zeng, J. Suttles, and R. D. Stout. 2009. Rapid release of cytoplasmic IL-15 from tumorassociated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur. J. Immunol. 39: 2126-2135.
7. Luo, Y., H. Zhou, J. Krueger, C. Kaplan, S. H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, and R. Xiang. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116: 2132-2141.
8. Gratchev, A., J. Kzhyshkowska, K. Köthe, I. Muller-Molinet, S. Kannookadan, J. Utikal, and S. Goerdt. 2006. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211: 473-486.
9. Stout, R. D., and J. Suttles. 2004. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 76: 509-513.
10. Gratchev, A., J. Kzhyshkowska, K. Duperrier, J. Utikal, F. W. Velten, and S. Goerdt. 2004. The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand. J. Immunol. 60: 233-237.
11. Gratchev, A., J. Kzhyshkowska, J. Utikal, and S. Goerdt. 2005. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand. J. Immunol. 61: 10-17.
12. Gratchev, A., J. Kzhyshkowska, S. Kannookadan, M. Ochsenreiter, A. Popova, X. Yu, S. Mamidi, E. Stonehouse-Usselmann, I. Muller-Molinet, L. Gooi, and S. Goerdt. 2008. Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J. Immunol. 180: 6553-6565.
13. Kakinuma, T., K. Nakamura, M. Wakugawa, S. Yano, H. Saeki, H. Torii, M. Komine, A. Asahina, and K. Tamaki. 2002. IL-4, but not IL-13, modulates TARC (thymus and activation-regulated chemokine)/CCL17 and IP-10 (interferoninduced protein of 10kDA)/CXCL10 release by TNF-alpha and IFN-gamma in HaCaT cell line. Cytokine 20: 1-6.
14. Nareika, A., K. P. Sundararaj, Y. B. Im, B. A. Game, M. F. Lopes-Virella, and Y. Huang. 2009. High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis 202: 363-371.
15. Katz, D. R., M. Drzymala, J. A. Turton, R. M. Hicks, R. Hunt, L. Palmer, and M. Malkovský. 1987. Regulation of accessory cell function by retinoids in murine immune responses. Br. J. Exp. Pathol. 68: 343-350.
16. Herrero, C., X. Hu, W. P. Li, S. Samuels, M. N. Sharif, S. Kotenko, and L. B. Ivashkiv. 2003. Reprogramming of IL-10 activity and signaling by IFNgamma. J. Immunol. 171: 5034-5041.
17. Schaer, D. J., F. S. Boretti, G. Schoedon, and A. Schaffner. 2002. Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel antiinflammatory action of glucocorticoids. Br. J. Haematol. 119: 239-243.
18. Brochériou, I., S. Maouche, H. Durand, V. Braunersreuther, G. Le Naour, A. Gratchev, F. Koskas, F. Mach, J. Kzhyshkowska, and E. Ninio. 2011. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: Implication in atherosclerosis. Atherosclerosis 214: 316-324.
19. Sell, H., C. Habich, and J. Eckel. 2012. Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 8: 709-716.
20. Bornfeldt, K. E., and I. Tabas. 2011. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 14: 575-585.
21. Gratchev, A., K. Schledzewski, P. Guillot, and S. Goerdt. 2001. Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol. Appl. Skin Physiol. 14: 272-279.
22. D'Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J. Exp. Med. 181: 537-546.
23. Bierie, B., and H. L. Moses. 2006. Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6: 506-520.
24. Bissell, D. M. 2001. Chronic liver injury, TGF-beta, and cancer. Exp. Mol. Med. 33: 179-190.
25. Wahl, S. M., D. A. Hunt, L. M. Wakefield, N. McCartney-Francis, L. M. Wahl, A. B. Roberts, and M. B. Sporn. 1987. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 84: 5788-5792.
26. Bombara, C., and R. A. Ignotz. 1992. TGF-beta inhibits proliferation of and promotes differentiation of human promonocytic leukemia cells. J. Cell. Physiol. 153: 30-37.
27. Feinberg, M. W., M. K. Jain, F. Werner, N. E. Sibinga, P. Wiesel, H. Wang, J. N. Topper, M. A. Perrella, and M. E. Lee. 2000. Transforming growth factorbeta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J. Biol. Chem. 275: 25766-25773.
28. Werner, F., M. K. Jain, M. W. Feinberg, N. E. Sibinga, A. Pellacani, P. Wiesel, M. T. Chin, J. N. Topper, M. A. Perrella, and M. E. Lee. 2000. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J. Biol. Chem. 275: 36653-36658.
29. Espevik, T., I. S. Figari, M. R. Shalaby, G. A. Lackides, G. D. Lewis, H. M. Shepard, and M. A. Palladino Jr. 1987. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med. 166: 571- 576.
30. Förstermann, U., H. H. Schmidt, K. L. Kohlhaas, and F. Murad. 1992. Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: Inhibition by transforming growth factor-beta. Eur. J. Pharmacol. 225: 161-165.
31. Pioli, P. A., K. E. Goonan, K. Wardwell, and P. M. Guyre. 2004. TGF-beta regulation of human macrophage scavenger receptor CD163 is Smad3-dependent. J. Leukoc. Biol. 76: 500-508.
32. Shepherd, T. G., B. L. Thériault, and M. W. Nachtigal. 2008. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene 414: 95-105.
33. Bode, K. A., K. Schroder, D. A. Hume, T. Ravasi, K. Heeg, M. J. Sweet, and A. H. Dalpke. 2007. Histone deacetylase inhibitors decrease Toll-like receptormediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122: 596-606.
34. Adcock, I. M. 2007. HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 150: 829-831.
35. Ito, K., S. Yamamura, S. Essilfie-Quaye, B. Cosio, M. Ito, P. J. Barnes, and I. M. Adcock. 2006. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203: 7-13.
36. Wrighton, K. H., X. Lin, and X. H. Feng. 2009. Phospho-control of TGF-beta superfamily signaling. Cell Res. 19: 8-20.
37. Dong, Y., L. Tang, J. J. Letterio, and E. N. Benveniste. 2001. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression. J. Immunol. 167: 311-319.
38. Xu, L., A. Kitani, C. Stuelten, G. McGrady, I. Fuss, and W. Strober. 2010. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33: 313-325.
39. Glozak, M. A., N. Sengupta, X. Zhang, and E. Seto. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
40. Simonsson, M., C. H. Heldin, J. Ericsson, and E. Grönroos. 2005. The balance between acetylation and deacetylation controls Smad7 stability. J. Biol. Chem. 280: 21797-21803.
41. Grönroos, E., U. Hellman, C. H. Heldin, and J. Ericsson. 2002. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol. Cell 10: 483-493.
42. Tajima, Y., K. Goto, M. Yoshida, K. Shinomiya, T. Sekimoto, Y. Yoneda, K. Miyazono, and T. Imamura. 2003. Chromosomal region maintenance 1 (CRM1)-dependent (Smurf1) is essential for negative regulation of transforming growth factor-beta signaling by Smad7. J. Biol. Chem. 278: 10716-10721.
43. Nakao, A., M. Afrakhte, A. Morén, T. Nakayama, J. L. Christian, R. Heuchel, S. Itoh, M. Kawabata, N. E. Heldin, C. H. Heldin, and P. ten Dijke. 1997. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635.
44. Zhang, Y. E. 2009. Non-Smad pathways in TGF-beta signaling. Cell Res. 19: 128-139.
45. Nakerakanti, S. S., A. M. Bujor, and M. Trojanowska. 2011. CCN2 is required for the TGF-b induced activation of Smad1-Erk1/2 signaling network. PLoS ONE 6: e21911.
46. Wrighton, K. H., X. Lin, P. B. Yu, and X. H. Feng. 2009. Transforming growth factor beta can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J. Biol. Chem. 284: 9755-9763.
47. Goumans, M. J., F. Lebrin, and G. Valdimarsdottir. 2003. Controlling the angiogenic switch: A balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc. Med. 13: 301-307.
48. Tang, Y., X. Yang, R. E. Friesel, C. P. Vary, and L. Liaw. 2011. Mechanisms of TGF-b-induced differentiation in human vascular smooth muscle cells. J. Vasc. Res. 48: 485-494.
49. Inman, G. J., F. J. Nicolás, J. F. Callahan, J. D. Harling, L. M. Gaster, A. D. Reith, N. J. Laping, and C. S. Hill. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62: 65-74.
50. Goumans, M. J., G. Valdimarsdottir, S. Itoh, F. Lebrin, J. Larsson, C. Mummery, S. Karlsson, and P. ten Dijke. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12: 817- 828.
51. Pardali, E., M. J. Goumans, and P. ten Dijke. 2010. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 20: 556-567.
52. Wang, X., S. Abraham, J. A. McKenzie, N. Jeffs, M. Swire, V. B. Tripathi, U. F. Luhmann, C. A. Lange, Z. Zhai, H. M. Arthur, et al. 2013. LRG1 promotes angiogenesis by modulating endothelial TGF-b signalling. Nature 499: 306-311.
53. Wu, X., L. M. Yung, W. H. Cheng, P. B. Yu, J. L. Babitt, H. Y. Lin, and Y. Xia. 2012. Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS ONE 7: e44622.
54. Saeed, O., F. Otsuka, R. Polavarapu, V. Karmali, D. Weiss, T. Davis, B. Rostad, K. Pachura, L. Adams, J. Elliott, et al. 2012. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32: 299-307.
55. Svensson, P. A., F. J. Olson, D. A. Hägg, M. Ryndel, O. Wiklund, L. Karlström, J. Hulthe, L. M. Carlsson, and B. Fagerberg. 2008. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int. J. Mol. Med. 22: 459-464.